Spreading like a wildfire, cell and gene therapies are transforming the world of disease prevention and management. Courtesy of this, the global cell therapy growth factor market size is set to double over the next ten years- from USD 664.8 million in 2024 to USD 1,370.2 million by 2034.
Global cell therapy growth factor demand will probably surge at 7.5% CAGR throughout the forecast period. Rising prevalence of cancer, diabetes, and other chronic diseases and escalating interest in innovative therapies like cell therapy will fuel this growth.
Cell Therapy Growth Factor Market Insights
| Attributes | Key Insights |
|---|---|
| Base Market Value in 2023 | USD 618.1 million |
| Market Size in 2024 | USD 664.8 million |
| Market Value in 2034 | USD 1,370.2 million |
| Value CAGR (2024 to 2034) | 7.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In the contemporary world, cell and gene therapies are at the forefront of medical advancements, helping healthcare professionals to treat various chronic diseases. As a result, demand for cytokines and growth factors used in these therapies is rising rapidly.
Growth factors are essential for the improvement, multiplication, and differentiation of cells in cell therapy treatments. These growth factors are often used in cell therapy to optimize the way of life or transplant environment and increase the therapeutic potential of cell-based therapies.
Growing popularity of cell-based therapies is anticipated to boost market growth during the forecast period. Cell therapy is becoming a promising method for treating several chronic diseases, including genetic conditions, cancer, and autoimmune disorders.
Another key factor fueling market growth is the rising spending on cell therapy research by government and private organizations. Similarly, growing popularity of regenerative medicine will benefit the market.
Advances in gene editing technologies like CRISPR-Cas9 are making cell therapies more precise and efficient. This, in turn, will improve the adoption rate of cell therapies, creating growth prospects for manufacturers.
The global growth factor industry recorded a CAGR of 6.0% from 2019 to 2023, with total valuation reaching USD 618.1 million by 2023. In the assessment period, a robust CAGR of 7.5% has been predicted for the target market.
One of the main factors fueling growth of the cell therapy growth factor market is the increasing incidence of chronic diseases. Similarly, growing need for early disease detection and prevention will benefit the market.
The rising incidence of chronic illnesses such as cancer, heart problems, and neurological disorders represents a major global health issue. Treatment modalities that are both innovative and effective are desperately needed, as these diseases burden people, healthcare systems, and economies globally. In this context, cell therapy presents itself as a promising new area in contemporary medicine, providing innovative methods for treating these chronic illnesses.
By utilizing stem cells, immune cells, and other cellular components' capacity for regeneration, cell therapy has the potential to transform the way chronic diseases are treated. Cell therapy interventions seek to repair damaged tissues, modulate immune responses, and restore physiological function by utilizing the distinct properties of these cells.
There is a noticeable trend towards more sophisticated drug delivery systems to improve patient adherence and treatment efficacy. Rising interest in regenerative medicine is opening new growth avenues for growth factor manufacturers.
The market is further supported by the cooperative efforts of pharmaceutical companies and academic institutions, which lead to strategic alliances and partnerships. These partnerships play a key role in increasing the pipeline of cell therapy growth factors, speeding up research and development, and ultimately enabling the commercialization of novel therapies.
Principal Consultant
The need for unique compounds known as growth factors grows as researchers discover more about the potential uses of cell therapy to treat various medical ailments. These growth factors support healthy cell division, growth, and transformation into distinct types.
The applications of cell therapy, including tissue repair, immune system stimulation, and organ development, have increased the need for novel growth factors. As cell therapy becomes more widely used to treat a range of medical conditions, businesses will have more opportunities to develop and market distinctive growth factor products specifically designed for these therapies.
Strict regulations controlling growth factors, which include safety, efficacy, and manufacturing standards, provide a major barrier to entry for industry participants. Getting the appropriate approvals and navigating this complicated regulatory environment takes time and money.
Although following the rules is vital, doing so can be difficult in terms of allocating resources, delaying the creation of new products, and adding to financial obligations. These regulatory barriers could discourage would-be competitors and impede the rate of innovation in the cell therapy growth factor industry, which would hinder the industry's progress.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below shows the predicted CAGR of the leading nations. The United States is the most dominant market, while India and France are set to witness high demand, recording CAGRs of 7.8% and 7.2%, respectively, through 2034.
Market Growth Outlook by Key Countries
| Countries | Value CAGR |
|---|---|
| United States | 5.2% |
| Germany | 6.2% |
| India | 7.8% |
| Malaysia | 6.7% |
| France | 7.2% |
The United States cell therapy growth factor market is estimated to advance at a CAGR of 5.2% throughout the forecast period. This can be attributed to several factors.
Firstly, America has a widespread population with several clinical issues that call for contemporary therapies, including cell therapies. This is emerging as a prominent factor propelling demand for cell therapy growth factors in the nation.
There is a greater need for novel treatments, like cell therapies, across the United States, and the trend will persist through 2034. This is due to their high efficacy and increasing acceptance among the general public.
The United States is also home to several leading biotechnology and pharmaceutical companies that are at the forefront of cell therapy research and development (R&D). These companies are striving to develop new growth factors using cost-effective and efficient methods.
FMI’s latest report estimates India to emerge as the most lucrative market for cell therapy growth factor companies, registering a CAGR of 7.8%. This is attributable to factors such as rising incidence of chronic diseases like cancer and diabetes, growing awareness of cell therapies, and favorable government support.
There is a spike in cases of chronic diseases like diabetes and cancer in India due to changing eating habits, excessive smoking, and other factors. This, in turn, is propelling demand for cell therapies that use growth factors to manage these diseases.
The Indian government is continuously launching programs to advance biotechnology development and improve healthcare accessibility. As a result, local and foreign businesses are swarming to take advantage of the growing prospects in this industry.
As per the latest analysis, demand for cell therapy growth factors in Germany is set to grow with a CAGR of 6.2% during the forecasted period. This is due to rising interest in personalized medicine and development of enhanced cell culture techniques and gene editing technologies.
Market growth in Germany is also fueled by its sturdy healthcare infrastructure, research skills, and determination to develop progressive remedies. Its unwavering dedication to innovation and first-rate healthcare is also positively impacting sales growth.
Particularly in relation to cellular-primarily based medicines, the country creates an ecosystem that is favorable to the advent and uptake of novel cell healing procedures. Rising cancer cases and availability of favorable reimbursement policies are other factors set to fuel market growth.
The section below sheds some light on leading segments along with their projected growth rates. Companies can use this information to frame their strategies accordingly to stay ahead of the curve.
The transforming growth factor-beta (TGF-β) dominates the market, representing a sizable 21.1% share in 2023. By application, oncology segment holds a 23.3% market value share in 2023. Based on end-user, hospitals accounted for a market share of around 43.2% in 2023.
| Top Segment (Growth Factor Type) | Transforming Growth Factor-beta (TGF-β) |
|---|---|
| Market Share in 2023 | 21.1% |
Demand remains particularly high for transforming growth factor-beta (TGF-β) owing to its therapeutic versatility. The target segment totaled a valuation of USD 130.4 million in 2023, representing a revenue share of 21.1%.
TGF-β is essential for controlling cellular features like migration, differentiation, apoptosis, and proliferation. This multifunctional cytokine can be utilized in cell therapy to govern these mechanisms and produce the intended therapeutic consequences.
TGF-β is useful in cell therapy to prevent graft rejection and modulate immune responses in a number of illnesses, along with autoimmune disorders. This is because of its immunosuppressive and anti-inflammatory properties.
TGF- β is becoming a promising target to treat several diseases like cancers and autoimmune disorders. Growing usage of TGF- β based therapies for the management of these diseases will boost segment growth.
| Top Segment (Application) | Oncology |
|---|---|
| Market Share in 2023 | 23.3% |
The oncology application is forecast to generate lucrative revenue-generation opportunities for cell therapy growth factor manufacturers. This can be attributed to rising prevalence of cancer and growing popularity of cell therapies in cancer management. The target segment accounted for a revenue share of 23.3% in 2023.
Cancer continues to emerge as a major health issue globally. According to the World Health Organization (WHO), around 20 new cancer cases and 9.7 million deaths were recorded in 2022. This, in turn, is creating a high demand for novel treatment approaches, including cell therapies and, subsequently, growth factors
Leukaemia and lymphoma are two cancers that have shown encouraging responses to cell therapy, particularly CAR-T cell therapy. Due to these achievements, there is now a great deal of interest in and funding for oncology-related research and development.
Numerous cell therapy products aimed at oncology indications have been approved by regulatory bodies across multiple nations. These approvals have fueled the market's development and made cell therapy treatments more accessible to cancer patients.
| Top Segment (End-user) | Hospitals |
|---|---|
| Market Share in 2023 | 43.2% |
Hospitals accounted for a market share of 43.2% in 2023, making them prominent end users of cell therapy growth factors. Hospitals are efficient at offering complete services pertaining to growth factors for cell therapy because they have vast infrastructure and resources at their disposal. This includes a wide range of topics, including the creation, production, and clinical use of cell therapy products.
Interdisciplinary teams of scientists, doctors, and healthcare workers within hospital settings support cell therapy research and development. Their combined knowledge is essential to the advancement of cell therapy technologies.
Investing in research and development to develop next-generation growth factors and combination therapies is a top priority for leading cell therapy growth factor companies. They are also using new biomanufacturing technologies as well as adopting tactics like partnerships, mergers, acquisitions, and collaborations to stay ahead of the competition,
Recent Developments in the Cell Therapy Growth Factor Market:
| Attribute | Details |
|---|---|
| Market Value in 2024 | USD 664.8 million |
| Market Size in 2034 | USD 1,370.2 million |
| Growth Rate (2024 to 2034) | 7.5% CAGR |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia & Pacific; Western Europe; Eastern Europe; Middle East & Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, ASEAN Countries, Australia & New Zealand, GCC Countries, South Africa, Türkiye |
| Key Market Segments Covered | Type of Growth Factors, Application, End-user, and Region |
| Key Companies Profiled | Thermo Fisher Scientific; Lonza Group; Merck KGaA (Sigma-Aldrich); STEMCELL Technologies Inc.; PeproTech, Inc.; Bio-Techne Corporation (R&D Systems); CellGenix GmbH; Miltenyi Biotec; Gibco (Thermo Fisher Scientific); RayBiotech, Inc.; ProSpec-Tany TechnoGene Ltd.; ABCAM plc; Sino Biological, Inc.; TreeFrog Therapeutics |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market is estimated to total USD 664.8 million in 2024.
By 2034, the global market size is set to reach USD 1,370.2 million.
Global demand is forecast to rise at 7.5% CAGR through 2034.
With a 21.2% share, transforming growth factor-beta (TGF-β) segment leads the market.
The global market increased at a 6.0% CAGR from 2019 to 2023.
The United States is poised to grow with a CAGR of 5.2% through 2034.
Germany is set to record a CAGR of 6.2% during the forecast period.
The stem cell therapy market size is forecast to reach USD 16.7 billion in 2024.
Stem cell therapy demand is set to rise at 12.1% CAGR through 2034.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value-Added Insights 5. Market Background 6. Global Market Demand (in Value or Size in USD million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type of Growth Factors 7.1. Platelet-derived Growth Factor (PDGF) 7.2. Brain-derived Neurotrophic Factor (BDNF) 7.3. Epidermal Growth Factor (EGF) 7.4. Fibroblast Growth Factor (FGF) 7.5. Vascular Endothelial Growth Factor (VEGF) 7.6. Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) 7.7. Insulin-like Growth Factor (IGF) 7.8. Transforming Growth Factor-Beta (TGF-β) 7.9. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 8.1. Cardiovascular Diseases 8.2. Autoimmune Disorders 8.3. Oncology 8.4. Diabetes 8.5. Orthopedic Conditions 8.6. Neurological Disorders 8.7. Others 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 9.1. Hospitals 9.2. Specialty Clinics 9.3. Biotechnology and Pharmaceutical Companies 9.4. Research Institutes 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 10.1. North America 10.2. Latin America 10.3. East Asia 10.4. South Asia & Pacific 10.5. Western Europe 10.6. Eastern Europe 10.7. Middle East & Africa 11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14. South Asia & Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17. Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18. Market Structure Analysis 19. Competition Analysis 19.1. Thermo Fisher Scientific 19.2. Lonza Group 19.3. Merck KGaA (Sigma-Aldrich) 19.4. STEMCELL Technologies Inc. 19.5. PeproTech, Inc. 19.6. Bio-Techne Corporation (R&D Systems) 19.7. CellGenix GmbH 19.8. Miltenyi Biotec 19.9. Gibco (Thermo Fisher Scientific) 19.10. RayBiotech, Inc. 19.11. ProSpec-Tany TechnoGene Ltd. 19.12. ABCAM plc 19.13. Sino Biological, Inc. 19.14. TreeFrog Therapeutics 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Cell Therapy Growth Factor Market
